APA (7th ed.) Citation

S, G., T, Q., O, H., G, K., R, A., D, A., . . . S, N. (2025). All-Cause Mortality and Gastrointestinal Adverse Effects in Adults With Type 2 Diabetes on Glucagon-Like Peptide-1 Receptor Agonists vs Sodium-Glucose Cotransporter-2 Inhibitors. Gastro hep advances, 4(10), 100736. https://doi.org/10.1016/j.gastha.2025.100736

Chicago Style (17th ed.) Citation

S, Garg, Qapaja T, Hamid O, Kaya G, Abdel-Razeq R, Alayan D, Abu-Rumaileh M, Lembo A, and Nissen S. "All-Cause Mortality and Gastrointestinal Adverse Effects in Adults With Type 2 Diabetes on Glucagon-Like Peptide-1 Receptor Agonists Vs Sodium-Glucose Cotransporter-2 Inhibitors." Gastro Hep Advances 4, no. 10 (2025): 100736. https://doi.org/10.1016/j.gastha.2025.100736.

MLA (9th ed.) Citation

S, Garg, et al. "All-Cause Mortality and Gastrointestinal Adverse Effects in Adults With Type 2 Diabetes on Glucagon-Like Peptide-1 Receptor Agonists Vs Sodium-Glucose Cotransporter-2 Inhibitors." Gastro Hep Advances, vol. 4, no. 10, 2025, p. 100736, https://doi.org/10.1016/j.gastha.2025.100736.